Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
1 other identifier
observational
200
1 country
1
Brief Summary
The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 19, 2022
CompletedFirst Submitted
Initial submission to the registry
December 13, 2022
CompletedFirst Posted
Study publicly available on registry
December 30, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2024
CompletedNovember 22, 2023
November 1, 2023
2.1 years
December 13, 2022
November 20, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Biospecimen & Clinical Data Collection
The primary objective is to collect 2000 whole blood samples from subjects who are diagnosed with active lung cancer. The purpose of this study is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with various active lung cancers so that investigations can analyze how the immune response can take place, and aid in understanding active lung cancer biomarkers for future early diagnosis and treatment options.
10 years
Interventions
Participants will have up to 100 mL of whole blood collected.
Eligibility Criteria
The study will enroll up to 200 participants. Recruitment will occur through Sanguine advertisements, partnerships with cancer foundations, and cancer centers. Participants may be contacted for future studies.
You may qualify if:
- Participants willing and able to provide written informed consent
- Participants are willing and able to provide appropriate photo identification
- Participant's age 18 - 100 years old
- Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)
- Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records
You may not qualify if:
- Participants who are pregnant or nursing
- Participants with a known history of HIV, hepatitis, or other infectious diseases
- Participants who have taken an investigational product in the last 30 days
- Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months
- Participants currently enrolled in a clinical trial
- Participants currently in remission
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sanguine Biosciences
Waltham, Massachusetts, 02451, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 13, 2022
First Posted
December 30, 2022
Study Start
February 19, 2022
Primary Completion
March 31, 2024
Study Completion
March 31, 2024
Last Updated
November 22, 2023
Record last verified: 2023-11